FibroBiologics, Inc.
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
The following sets forth information regarding all unregistered securities we sold during the three months ended March 31, 2026. Unless stated otherwise, the sales of the securities listed below were deemed to be exempt from registration pursuant to Section 4(a)(2) of the Securities Act, as transactions by an issuer not involving a public offering.
Below is a summary of shares sold to YA II PN, LTD., or Yorkville, pursuant to the standby equity purchase agreement, or the SEPA, dated December 20, 2024, with Yorkville, during the three months ended March 31, 2026. Shares were sold at a 4% discount to the applicable market price.
| Date | Cash Received | Shares Issued | Price Per Share |
|---|---|---|---|
| March 12, 2026 | $180,799 | 26,667 | $7.064 |
| March 12, 2026 | $9,686 | 1,441 | $7.000 |
| March 18, 2026 | $323,050 | 65,000 | $5.178 |
| March 24, 2026 | $128,053 | 26,667 | $5.002 |
| March 24, 2026 | $64,000 | 13,333 | $5.000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.